TM Owner Boehringer Ingelheim
Twynsta 80mg/10mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Twynsta is a fixed-dose combination tablet containing 80 mg of telmisartan (an angiotensin II receptor blocker) and 10 mg of amlodipine (a dihydropyridine calcium channel blocker), indicated for treatment of hypertension in adults.
- Telmisartan blocks angiotensin II receptors, reducing vasoconstriction; amlodipine blocks voltage-gated L-type calcium channels, causing vasodilation.
- The combination provides dual mechanism blood pressure reduction.
- Twynsta is used in patients whose blood pressure is not controlled by either agent alone, or as initial therapy in patients likely to benefit from combination antihypertensive therapy.
Side Effects
- Common side effects include headache, dizziness, and fatigue affecting 1–10% of patients.
- Ankle edema (peripheral swelling) is common with amlodipine, occurring in up to 10% of users.
- Flushing and palpitations may occur.
- Gastrointestinal effects include dyspepsia, diarrhea, and nausea in fewer than 1–3% of patients.
- Back pain and muscle cramps are reported.
- Serious but uncommon side effects include syncope (fainting), hyperkalemia if combined with ACE inhibitors or potassium supplementation, and renal impairment in susceptible patients.
- Angioedema, though rare, is a serious reaction requiring immediate medical attention.
Precautions & Warnings
- Contraindicated in pregnancy (especially 2nd and 3rd trimesters) due to teratogenic and fetotoxic effects.
- Use with extreme caution in patients with renal impairment, bilateral renal artery stenosis, or single functioning kidney; monitor creatinine and potassium.
- Hyperkalemia risk increases if combined with ACE inhibitors, other ARBs, NSAIDs, or potassium-sparing diuretics.
- Monitor blood pressure and renal function regularly.
- Caution in patients with hepatic impairment, especially amlodipine metabolism.
- Avoid in patients with severe hypotension or heart block (2nd- or 3rd-degree).
- Do not use concurrently with aliskiren in patients with diabetes or renal disease.
Avoid Interactions
- NSAIDs (including COX-2 inhibitors) reduce antihypertensive efficacy and increase hyperkalemia and renal dysfunction risk.
- ACE inhibitors, other ARBs, and potassium-sparing diuretics increase hyperkalemia risk; monitor potassium closely.
- Lithium clearance may be reduced, increasing toxicity; monitor lithium levels.
- Amlodipine is metabolized by CYP3A4; inhibitors (macrolide antibiotics, protease inhibitors, azole antifungals) increase amlodipine levels; inducers (rifampicin, carbamazepine) decrease levels.
- Grapefruit juice increases amlodipine levels; avoid concurrent consumption.
References
Frequently Asked Questions
Twynsta is a fixed-dose combination tablet containing 80 mg telmisartan (angiotensin receptor blocker) and 10 mg amlodipine (calcium channel blocker). It treats high blood pressure in adults by lowering blood pressure through two complementary mechanisms. Telmisartan blocks angiotensin II; amlodipine relaxes blood vessels. Twynsta is used when monotherapy does not achieve target blood pressure.
Take one Twynsta 80/10 mg tablet by mouth once daily, with or without food. Swallow the tablet whole; do not crush or chew. The tablet can be taken at any time of day, but take it at the same time each day for consistency. Blood pressure control typically develops within 2–4 weeks; maximum effect appears at 8 weeks of treatment.
Common side effects include headache, dizziness, fatigue, and ankle swelling (edema), affecting 1–10% of patients. Flushing and palpitations may occur (amlodipine effects). Gastrointestinal effects include dyspepsia, diarrhea, and nausea in fewer patients. Most side effects are mild and resolve within a few weeks. Report persistent symptoms to your healthcare provider.
Do not take Twynsta with potassium supplements, ACE inhibitors, or other potassium-sparing medications without medical approval, as hyperkalemia risk increases. NSAIDs reduce Twynsta effectiveness and increase kidney and potassium problems. Limit alcohol, salt, and grapefruit juice, which can affect amlodipine levels. Inform your doctor of all medications before starting Twynsta.
Patients with kidney disease need careful monitoring. Do not take Twynsta if you have bilateral renal artery stenosis or single functioning kidney. Telmisartan reduces blood flow to kidneys and may worsen function in these conditions. Blood creatinine and potassium levels must be checked regularly. Discuss your kidney status with your healthcare provider before starting treatment.
No. Twynsta is absolutely contraindicated during pregnancy, especially the 2nd and 3rd trimesters, as both telmisartan and amlodipine may harm the fetus. Use effective contraception while taking Twynsta. Breastfeeding: both drugs pass into breast milk; safer alternatives exist. Consult your healthcare provider about blood pressure management during pregnancy and lactation.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
